Technical Data Sheet

Purified NA/LE Mouse Anti-Human CD178

Product Information

Material Number:	**556371**
Alternate Name:	Fas Ligand; CD95 Ligand
Size:	0.25 mg
Concentration:	1.0 mg/ml
Clone:	NOK-1
Immunogen:	Mouse T lymphoma cells (L5178Y) expressing human FasL
Isotype:	Mouse IgG1
Reactivity:	QC Testing: Human
Storage Buffer:	No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.

Description

Fas (CD95; APO-1) is a 45 kDa cell surface protein that mediates apoptosis when cross-linked with agonistic anti-Fas antibodies or by Fas ligand (FasL; CD178). Fas belongs to the TNF (Tumor Necrosis Factor)/NGF (Nerve Growth Factor) receptor family, and is expressed in various tissues and cells including the thymus, liver, ovary and lung. CD178 (FasL), a member of the TNF cytokine family, induces apoptosis by binding to Fas, its cell-surface receptor. FasL may exist as either membrane bound or soluble forms and is expressed by activated T and NK cells. FasL may also be constitutively expressed in some immunologically privileged sites, e.g., eye and testis. Fas and FasL play an important role in the induction of apoptosis, and thus regulate a variety of immunological responses.

The NOK-1 antibody clone has been reported to recognize human FasL, recognizing both the membrane bound (FasL) and soluble (sFasL) forms. It is reported that the epitope for NOK-1 has been mapped to the COOH-terminus of FasL, at the region implicated in Fas binding. FasL and sFasL have been reported to migrate at reduced molecular weights of 40 and 26 kDa, respectively. However, the molecular weights observed in a particular sample may vary according to FasL and sFasL glycosylation and breakdown patterns as described in the literature. The NOK-1 antibody clone is not recommended for the western blot application.



Flow cytometric analysis of human Fas Ligand (FasL) on natural killer cells (CD16+) analyzed on a FACScan™ (BDIS, San Jose, CA). *Peripheral blood mononuclear cells were cultured for 3 hours in media alone (left panel) or with ionomycin plus the metalloprotease inhibitor, KB8301 (right panel). KB8301 blocks FasL cleavage resulting in high levels of cell surface FasL. The cells were stained with purified anti-human FasL (clone NOK-1, Cat. No. 556372), followed by biotinylated goat anti-mouse Igs. The cells were then incubated with normal mouse serum before adding FITC-conjugated anti-human CD16 (Cat. No. 555406) and Streptavidin-PE (Cat. No. 554061).*



Immunoprecipitation/western blot analysis of human FasL. *Lane 1, FasL was precipitated from human peripheral blood mononuclear cells (PBMC's) with clone NOK-1 (Cat. No. 556372) and detected by western blot analysis with clone G247-4 (Cat. No. 556387). Lane 2, PBMC were immunoprecipitated with a mouse IgG1 isotype control, followed by western blot analysis with clone G247-4. The bands above and below the 40 kDa FasL band in lane 1 and lane 2 represent the heavy and light chain of IgG used for immunoprecipitation.*

Preparation and Storage

Store undiluted at 4°C.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

This preparation contains no preservatives, thus it should be handled under aseptic conditions.

BD Biosciences

bdbiosciences.com

United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean
877.232.8995	888.268.5430	32.53.720.550	0120.8555.90	65.6861.0633	0800.771.7157

For country-specific contact information, visit **bdbiosciences.com/how_to_order/**

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2011 BD

Application Notes

Application

Flow cytometry	Routinely Tested
Immunoprecipitation	Tested During Development
Neutralization	Reported
Western blot	Not Recommended

Product Notices

1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.

References

Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. *J Exp Med.* 1995; 182(6):1777-1783. (Immunogen: Flow cytometry, Neutralization)

Orlinick JR, Elkon KB, Chao MV. Separate domains of the human fas ligand dictate self-association and receptor binding. *J Biol Chem.* 1997; 272(51):32221-32229. (Clone-specific: Immunoprecipitation, Neutralization)

Oyaizu N, Adachi Y, Hashimoto F, et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. *J Immunol.* 1997; 158(5):2456-2463. (Clone-specific: Flow cytometry)

Sieg S, Smith D, Yildirim Z, Kaplan D. Fas ligand deficiency in HIV disease. *Proc Natl Acad Sci U S A.* 1997; 94(11):5860-5865. (Clone-specific: Flow cytometry)

Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, and Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. *Cell.* 1994; 76(6):969-976. (Biology)

Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. *EMBO J.* 1995; 14(6):1129-1135. (Biology)

Villunger A, Egle A, Marschitz I, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. *Blood.* 1997; 90(1):12-20. (Clone-specific: Flow cytometry, Neutralization)

Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. *J Immunol.* 1997; 158(10):4521-4524. (Clone-specific: Neutralization)

Zavazava N, Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. *Nat Med.* 1996; 2(9):1005-1010. (Clone-specific: Flow cytometry, Neutralization)